Trial
NCT02976038
Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Stealth BioTherapeutics Inc.
Collaborators
—
Condition
Primary Mitochondrial Disease
Intervention
elamipretide
Why stopped
Registration trial did not meet the primary end points
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-17